Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Cidara Therapeutics (CDTX)
-
Cantor Fitzgerald Assumes Cidara Therapeutics (CDTX) at Overweight
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Cidara Therapeutics to Participate in Upcoming Investor Conferences
-
Cidara Therapeutics (CDTX) Provides Corporate Update, Reports Q4
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Sto
-
Cidara Therapeutics (CDTX) Prices $17.5M Common and Preferred Stock Offering
-
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics (CDTX) Announces Proposed Stock Offering
-
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
-
Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
-
Cantor Fitzgerald Reiterates Cidara Therapeutics (CDTX) at Overweight, Believes the Street Underappreciates Company's Sales Potential, Sees Upward Earnings Revisions
-
Johnson & Johnson (JNJ), Cidara Therapeutics (CDTX), Pfizer (PFE), and PDS Biotechnology (PDSB) - Cantor Fitzgerald's Top Flu Vaccine Candidates for 2022
-
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of
-
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of
-
Cidara Therapeutics (CDTX) Prices 14.84M Share Offering at $1.55/sh
-
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics (CDTX) Commences Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
-
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
-
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
-
Cidara Therapeutics to Participate in Upcoming Investor Conferences
-
Cidara Therapeutics to Participate in Upcoming Investor Conferences
-
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
-
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
-
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
-
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
-
Cidara Therapeutics (CDTX) Halted on Volatility After Surge Higher
-
Cantor Fitzgerald Highlights Cidara Therapeutics (CDTX) on Coronavirus Opportunity
-
Cidara Therapeutics (CDTX) Announces Proposed $30M Rights Offering
-
Cidara Therapeutics Announces Proposed Rights Offering
-
Cidara Therapeutics (CDTX) PT Lowered to $8 at Cantor Fitzgerald
-
Cidara Therapeutics (CDTX) Announces Offering of Common Stock, Warrants
-
Cidara Therapeutics Announces Offering of Common Stock and Warrants
-
Cidara Therapeutics (CDTX) Prices $20M Private Placement of Common Stock
-
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
-
Cidara Therapeutics to Present at Two Upcoming Conferences
-
Cantor Fitzgerald Assumes Cidara Therapeutics (CDTX) at Overweight, Sees Underappreciated Sales Potential
-
Cantor Fitzgerald Starts Cidara Therapeutics (CDTX) at Buy
-
Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
-
Cidara Therapeutics (CDTX) Prices 2.48M Common Stock Offering at $10.10/Share
-
Cidara Therapeutics Announces Pricing of Public Offering of Common Stock
-
Cidara Therapeutics (CDTX) to Offer Common Stock
-
Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
-
Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference

